WO2023007431 - ENGINEERED IMMUNE CELL THAT SPECIFICALLY TARGETS MESOTHELIN AND USES THEREOF
National phase entry:
Publication Number
WO/2023/007431
Publication Date
02.02.2023
International Application No.
PCT/IB2022/057006
International Filing Date
28.07.2022
Title **
[English]
ENGINEERED IMMUNE CELL THAT SPECIFICALLY TARGETS MESOTHELIN AND USES THEREOF
[French]
CELLULE IMMUNITAIRE MODIFIÉE QUI CIBLE SPÉCIFIQUEMENT LA MÉSOTHÉLINE ET SES UTILISATION
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
TAKE, Chihiro
YAMAGUCHI, Akiko
SHAPIRO, Gary
Priority Data
63/227,116
29.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3714 | |
| EPO | Filing, Examination, Granting | 34482 | |
| Japan | Filing, Examination, Granting | 3390 | |
| South Korea | Filing, Examination, Granting | 4587 | |
| USA | Filing, Examination, Granting | 15790 |
Total:
61,963
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are isolated nucleic acid molecules comprising a polynucleotide encoding a chimeric antigen receptor (CAR) comprising an antibody that specifically recognizes human mesothelin, a CD8 hinge region, a CD8 transmembrane region, a 4-1BB intracellular region and a CD3ζ intracellular region; a polynucleotide encoding IL-7; and a polynucleotide encoding CCL19. Also disclosed herein include vectors, modified immune cells, and pharmaceutical compositions comprising the nucleic acid molecules and methods of use.[French]
La divulgation concerne des molécules d'acide nucléique isolées comprenant un polynucléotide codant pour un récepteur antigénique chimérique (CAR) comprenant un anticorps qui reconnaît spécifiquement la mésothéline humaine, une région charnière CD8, une région transmembranaire CD8, une région intracellulaire 4-1BB et une région intracellulaire CD3ζ; un polynucléotide codant pour IL-7; et un polynucléotide codant CCL19. La divulgation concerne également des vecteurs, des cellules immunitaires modifiées, ainsi que des compositions pharmaceutiques comprenant les molécules d'acide nucléique et des méthodes d'utilisation.